Tsukuba, Japan

Ryutaro Wakayama

USPTO Granted Patents = 7 



Average Co-Inventor Count = 7.1

ph-index = 4

Forward Citations = 38(Granted Patents)


Location History:

  • Tsukuba, JP (2005 - 2009)
  • Tokyo, JP (2011 - 2014)

Company Filing History:


Years Active: 2005-2014

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):

Title: The Innovations of Ryutaro Wakayama

Introduction

Ryutaro Wakayama is a notable inventor based in Tsukuba, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that aid in treating thrombocytopenia. With a total of seven patents to his name, his work has had a considerable impact on medical science.

Latest Patents

Wakayama's latest patents include a 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof. This compound exhibits an excellent effect of proliferating human c-mpl-Ba/F3 cells and has the activity of increasing platelets. It promotes the formation of megakaryocytic colonies, making it a valuable asset in treating thrombocytopenia. The innovative nature of this compound highlights Wakayama's commitment to advancing medical treatments.

Career Highlights

Throughout his career, Ryutaro Wakayama has worked with prominent companies in the pharmaceutical industry. He has been associated with Astellas Pharma GmbH and Yamanouchi Pharmaceutical Company Ltd. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research.

Collaborations

Wakayama has collaborated with esteemed colleagues such as Keizo Sugasawa and Susumu Watanuki. These partnerships have fostered an environment of innovation and have led to the successful development of his patented compounds.

Conclusion

Ryutaro Wakayama's contributions to the field of pharmaceuticals through his innovative patents and collaborations demonstrate his dedication to improving medical treatments. His work continues to influence the industry and offers hope for patients suffering from thrombocytopenia.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…